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Childhood adverse experiences (ACE)
Epigenetic mechanism
Feasibility study
A B S T R A C T
Background: Conversion disorder/functional neurological disorder (CD/FND) occurs often in neurological settings
and can lead to long-term distress, disability and demand on health care services. Systemic low-grade inflam-
mation might play a role, however, the pathogenic mechanism is still unknown.
Aim: 1) To explore the feasibility to establish and assess a cohort of CD/FND with motor symptoms, involving
persons with lived experience (PPI). 2) To generate proof of concept regarding a possible role for cytokines,
microRNA, cortisol levels and neurocognitive symptoms in patients with motor CD/FND.
Method: Feasibility study.
Results: The study showed active involvement of patients despite high clinical illness burden and disability,
neurocognitive symptoms, childhood adverse experiences (ACE) and current life events. The study provided
valuable knowledge regarding the feasibility of conducting a study in these patients that will inform future study
phases. In the sample there were elevated levels of IL6, IL12, IL17A, IFNg, TNFa and VEGF-a, suggesting systemic
low-grade inflammation. Also, microRNAs involved in inflammation and vascular inflammation were correlated
with TNFa and VEGFa respectively, suggesting proof of concept for an epigenetic mechanism. Owing to the
COVID-19 outbreak, the patient sample was limited to 15 patients.
Conclusion: It is a novelty that this study is conducted in the clinical setting. This innovative, translational study
explores stress-related SLI in CD/FND patients and the feasibility of a larger project aiming to develop new
treatments for this vulnerable population. Given the positive findings, there is scope to conduct further research
into the mechanism of disease in CD/FND.
1. Introduction
Conversion disorder/functional neurological disorder (CD/FND) as
described in the DSM-5 (American psychiatric Association, 2013) can lead
to long-term distress, disability, diminished quality of life and demand on
health care services.(Gelauff et al., 2014; Mace and Trimble, 1996).
Treatment options for patients with CD/FND are limited and typically
have a small effect, leading to a high unmet clinical need (Goldstein,
2020; Kroenke, 2007; Ruddy, 2005). Depending on the presenting
symptoms, patients may receive psychosocial interventions (such as
cognitive behavioural therapy; Hubschmid et al., 2015; Kompoliti, 2015)
to explore the underlying causes (such as historical trauma), occupa-
tional therapy, or physiotherapy (Nielsen et al., 2013) to help with any
physical symptoms (Goldstein, 2020; Kroenke, 2007; Ruddy, 2005).
Although several possible mechanisms for the pathogenesis of CD/
FND are under consideration, its specific origin is unknown (Ratcliff and
van der Feltz-Cornelis, 2020). Mechanisms that have been proposed are
systemic low-grade inflammation (SLI) (Del Grande da Silva et al., 2016;
Kovacs et al., 2016a,b; Tiyekli et al., 2013; Viljoen and Panzer, 2005;
Vogelzangs et al., 2016). Elevated CRP was found in some, but not all,
children with CD/FND (Kozlowska et al., 2019); this may indicate that
the relationship is not straightforward. There might be multiple strains
with CD/FND, that each have different causes. (Ratcliff and van der
Feltz-Cornelis, 2020). For example, another study found that hsCRP is
elevated especially in case of motor function CD/FND (Tak et al., 2009).
It might also be that an inflammatory process might occur at a certain
pathological phase (Ratcliff and van der Feltz-Cornelis, 2020). For
example, autonomous dysregulation could interfere with
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downregulation by corticosteroid production in the adrenal glands,
resulting in peripheral inflammation that cannot be ‘switched off’
(Pongratz and Straub, 2014). Suggestions of such amechanism have been
found in CD/FND (Kozlowska et al., 2015; Maurer et al., 2015) and they
may seem to hang together with adverse childhood events (ACE) (Bau-
meister et al., 2016). Although current stress levels and ACE have been
explored in CD/FND (Ludwig et al., 2018), so far their association with
systemic low-grade inflammation in CD/FND has not yet been explored.
In terms of a possible underlying mechanism, childhood trauma has been
suggested to prime microglia and this might be associated with adult
mental disorder (Calcia et al., 2016), however whether this is the case in
CD/FND has not been the subject of research so far. Nevertheless, sub-
jective neurocognitive problems such as information processing speed
occur in CD/FND (American Psychiatric Association, 2013; De Vroege
et al., 2020) (Baumeister et al., 2016), and this might be an indication of
neuroinflammation affecting brain activity i.e. neurocognitive function.
Additionally, these neurocognitive symptoms have been shown relevant
to treatment outcome (De Vroege et al., 2017).
Exposure to early-life adversity is known to predict DNA methylation
patterns that may be related to risk for development of mental disorders
(Dunn et al., 2019) and gene-environment interactions and epigenetics
have been studied in anxiety disorders (Lin et al., 2020). However, so far,
the links between epigenetic and post-transcriptional regulatory mech-
anisms and CD/FND have been poorly explored. For example microRNAs
(miRNAs) are critical post-transcriptional and epigenetic regulators, yet
their role in CD/FND has not been explored. In this study, we focus on
plasma miRNAs as they have been studied extensively as biomarkers of
inflammation in a variety of contexts including specifically neuro-
inflammation (Slota and Booth, 2019) and neurodegenerative diseases
(Sheinermann et al., 2017) and studies investigating circulating miRNA
levels in individuals with CD/FND and their relationship to circulating
cytokine levels have not been conducted so far.
The objectives of this feasibility study were to inform further research
steps by enabling us to generate a comprehensive testing procedure and
evaluation of the proposed processes of recruitment, retention and data
collection. A further objective was to generate proof of concept regarding
a possible role for cytokines, microRNA, cortisol levels and neuro-
cognitive symptoms in patients with motor CD/FND that may warrant a
subsequent larger study exploring the underlying mechanism and
possible treatment options related to it (Van der Feltz-Cornelis et al.,
2020b). Lastly, we aimed to establish a patient and public involvement
(PPI) advisory group to determine the acceptability of the study processes
for patients and carers.
2. Material and methods
This was a feasibility study sponsored by the University of York. Study
preparation started in March 2019. It was registered at the Research
Registry (UIN: researchregistry5289). The study protocol was published
(Van der Feltz-Cornelis et al., 2020b); study methods are summarised in
the current article.
Participants were recruited through clinics and services within the
Tees, Esk and Wear Valleys NHS Foundation Trust (TEWV), and Humber
Teaching NHS Foundation Trust. Participants could also self-refer to the
study via the study website (Conversion, 2019). The target population
was adult patients, aged 18 and above with diagnosed CD/FND with
motor symptoms. Both incident and prevalent cases could be included.
Patients with any inflammatory condition, such as for example a diag-
nosis of Cushing’s syndrome; any blood-clotting disorders (e.g. haemo-
philia) or transfusion transmissible infections (e.g. HIV); on steroidal or
other anti-inflammatory medication at the point of recruitment to the
study, as taken from patient files or self-reported, were excluded. Patients
with non-motor CD/FND, pseudo-seizures or epileptic seizures, as well as
patients with brain injury or neuro-degenerative conditions (such as
dementia or Parkinson’s disease) were excluded. Recruitment started
August 2019 and was planned to end June 1st, 2020. All participants
continued to receive their usual care throughout the study, which could
consist of a combination of Cognitive Behavioral Treatment (CBT) and
physiotherapy; it was out of scope of this feasibility study to record de-
tails about usual care provision. To confirm the diagnosis, psychiatric
classification (PSE) following DSM-5 classification criteria (American
Psychiatric Association, 2013) and Mini Mental State Examination
(MMSE) (Schmand et al., 1995) were performed according to a pre-
determined format that included checking the medical history regarding
diagnosis of CD/FND and establishing the main physical symptom.
2.1. Outcome measures
Outcome measures are summarised in Table 1.
2.2. Neurocognitive functioning
Assessment of neurocognitive functioning was performed using
selected, standardised tests of information processing, executive func-
tioning and memory. First the Test of Memory Malingering (TOMM test)
(Tombaugh and Tombaugh, 1996; Teichner and Wagner, 1997) was
performed to rule out malingering, because of the relevance of potential
malingering in the clinical setting. For similar reasons, for effort the Digit
Span sub-test of the Wechsler Adult Intelligence Scale (Wechsler, 2008)
was used to assess effort (i.e. anomalous discrepancies between forwards
and backwards components of the test) as well as working memory (see
below). Sub-tests from the Delis-Kaplan Executive Functioning System
(DKEFS) (Delis et al., 2004), were used to assess information processing,
attention, motor speed and key aspects of executive functioning. This
domain was assessed using the Digit Symbol Substitution Test (Coding)
from the Wechsler Adult Intelligence Scale-IV (Wechsler, 2008). This is a
timed task that examines information processing and psychomotor speed
by asking respondents to match and complete corresponding symbols to
the numbers presented. The Trail Making Test (TMT) from the DKEFS
was also used to assess information processing, visual attention,
switching and motor speed (Reitan, 1992). The Stroop Colour–Word
Interference Test (CWIT) from the DKEFS was used to assess for verbal
inhibition and switching (Delis et al., 2004; Stroop, 1938). Executive
functioning was further explored using the Tower of London test, which
assesses visual problem solving, rule following and visual working
memory (Shallice, 1982). Working memory was assessed using the
Wechsler Adult Intelligence Scale-IV Digit Span Test (Wechsler, 2008).
This test consists of three conditions, in which participants are asked to
verbally repeat numbers given in the same order, in reverse order, and in
ascending order, respectively.
To compare the scores of patients with CD/FND with normative
values, relevant scaled scores on each test were used. Across the WAIS IV
and DKEFS sub-tests, the mean normative scales scores were 10 (SD¼ 3).
It is acknowledged that there is no universal agreement regarding the
threshold used to define cognitive impairment in neuropsychological
research (Brooks, 2009; Crawford, 2011; Jak, 2009). Existing research
studies that have utilised similar neuropsychological tests to the ones
used in the current study have defined cognitive impairment as scores
that are one SD or more (16th percentile or less) below the mean (Dozier,
2016; Holst, 2020; Karr, 2017; Keifer, 2013; Wexler, 2009). Given the
purpose of this study was to assess feasibility, as opposed to a full-scale
evaluation study, this criterion is appropriate to define cognitive
impairment. Hence, mean scaled scores 1SD or more below the popula-
tion mean for each neurocognitive test (e.g. less than or equal to a scaled
score of 7) were considered to represent impairment in this study.
2.3. Biomarkers
Details of cytokine and hsCRP assays, microRNA plasma extraction
and analysis and hair cortisol analysis (D’Anna-Hernandez et al., 2011)
are provided in Supplement 1.
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2.4. Statistical analysis
RAND SF 36 scores (Ware& Sherbourne, 1992) versus Medical
Outcome Studies (MOS) (Tarlov et al., 1989) norm scores were compared
and p-values presented for the differences by one sample t-test. Charac-
teristics of the proposed outcome measures hsCRP (Seo, 2012) and cy-
tokines including standard deviation were taken for future power
calculation. The lab provided median and range scores from a commer-
cial normal sample (N¼ 27) for IFNγ, IL1-b, IL-6, IL-12, IL 17a, TNFα, and
VEGF-a. Range was calculated of the samples with concentrations above
the Lowest Level Of Detection (LLOD). Significance level for the differ-
ence between our sample and the normal sample was estimated by
Wilcoxon Signed Rank test. Significance level for the difference between
hsCRP in the sample and cut-off score was estimated by One-Sample
t-test. Outcomes for cytokines were then plotted against miRNA, calcu-
lating Pearson P values and slopes, analysed with GraphPad Prism. The
hair sample outcomes were compared with hair sample outcomes from
healthy volunteers with t-test.
3. Results
3.1. Feasibility
The feasibility of establishing the cohort and performing psycho-
diagnostic assessment for description of the cohort was explored. This
included feasibility of obtaining ethical approval and approval of local
R&D departments at the different recruiting sites. The preparation phase
of the study started in March 2019. The protocol for HRA approval was
submitted on April 8, 2019 and approval granted on 10th June by the
NHS North West 11 Research Ethics Committee, Preston (IRAS nr.
261252). TEWV confirmed capacity and capability on July 11, 2019 and
recruited the first participant in the first week of August.
3.1.1. Lab infrastructure
We built an infrastructure for venepunctures, transport to lab and
analysis of the blood. Arrangements were made with four different
laboratories for cytokines and microRNA. All sites were able to provide
phlebotomy services and research nurses for data collection. Blood from
venepunctures was transported to the biochemistry laboratory based at
James Cook University Hospital on the same day. Blood was centrifuged
and divided over two vials, one for the Core Biochemical Assay Labo-
ratory (CBAL), Cambridge University, assessing cytokines and the other
for the University of York laboratory assessing microRNA. This was
stored at the James Cook University Hospital biochemistry laboratory
until the sample was complete and then transported to the other
involved laboratories for analysis, in one procedure for all patients for
standardisation purposes. This was feasible in the short timeframe of
this study because colleagues in TEWV had existing contractual ar-
rangements with the hospital. With a longer lead-in time it would be
feasible to set up a similar infrastructure where existing arrangements
are currently unavailable. As control measurements, the CBAL provided
median and range data from a commercial sample of 27 healthy subjects
for comparison of the cytokine levels, age and gender of whom were
unavailable for analysis. Standardisation and analysis method was the
same in both samples. All hair samples were analysed at the ARU





Physical Symptom Questionnaire (PSQ-51)
Additional to the mean score, the following dimensions were discerned: CD/FND symptoms; postural orthostatic tachycardia
syndrome (POTS); digestive symptoms; pain; fatigue; sleep score and sexual symptoms. (Allen et al., 2020; Van Hemert
et al., 2004)
Pain:
Brief Pain Inventory (BPI)
Average severity of pain in the last week was assessed. An average score of 3 or more on the BPI in the last week is the cut
score for clinically significant pain.
General functioning: RAND 36-Items The RAND 36-Item Health Survey taps eight health concepts: physical functioning, bodily pain, role limitations due to
physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning,
energy/fatigue, and general health perceptions. The higher the score, the better the functioning. These RAND 36 items are
identical to the MOS SF-36.(Ware and Sherbourne, 1992) They were adapted from longer instruments completed by patients
participating in the Medical Outcomes Study (MOS), (Tarlov et al., 1989) an observational study of variations in physician
practice styles and patient outcomes in different systems of health care delivery, for HIV patients (Hays and Shapiro, 1992)
and patients with chronic medical conditions (Stewart et al., 1989) and depressive disorders. (Wells et al., 1989)
Quality of life:
EuroQol EQ-5D-5L
EQ-5D-5L percentages of patients scoring on the subscales mobility, selfcare, activities, pain and depression or anxiety were
established. NICE does not recommend using UK EQ-5D-5L norm scores as there are issues with the scoring system, (NICE,
2020) hence we compared the mean score for the general health item with similar scores from other countries.
Childhood trauma: Adverse Childhood Experiences
scale (WHO-ACE-IQ)
The WHO-ACE-IQ (WHO, 2018) provides a total score and differentiates between 9 domains: problems with marriage or
parenthood, such as arranged marriage and unwanted pregnancies; parental neglect, parental illness, witnessing domestic
abuse, being a victim of domestic abuse, being a victim of sexual abuse, experiencing bullying, external violence, and war
experiences, all during childhood.
Current life events: Holmes and Rahe Life Events Stress
Scale
The Holmes and Rahe Life Events Stress Scale assesses for 54 life events that can cause stress as they require a role transition
that could be positive or negative in nature, whether they occurred over the last 12 months. A total score (Life Change Units)
is provided based upon validated scores per life event (LCU).(Holmes and Rahe, 1967)
Chronic medical conditions CBS checklist. Assesses presence and number of chronic medical conditions.(CBS, 2005)
Anxiety:
GAD7
General Anxiety Disorder questionnaire (GAD-7) (L€owe et al., 2008) GAD-7 scores of 5 or higher indicate mild anxiety
symptoms; scores of 10 or higher indicate a probability for an anxiety disorder.(Kroenke et al., 2010)
Depression:
PHQ9
Patient Health Questionnaire-9 (PHQ-9) (Kroenke et al., 2001) PHQ-9 scores of 5 or higher indicate mild depressive
symptoms; scores of 10 indicate a probability for a depressive disorder. (Kroenke et al., 2010)
Clinimetric measures: Height, Weight, BMI, Waist circumference and Blood pressure recorded during first interview and Body Mass Index (BMI)
calculated.
Inflammation markers: Cytokines TNFα; IL1β; IL6; IFNɣ;
VEGF-a; ANG2 hSCRP
Tumor Necrosis Factor alpha (TNFα), (Baumeister et al., 2016; Zelova et al., 2013) Interleukin 1 beta (IL1β), (Kovacs et al.,
2016a,b) Interleukin 6 (IL6), (Money et al., 2016; Tanaka et al., 2014) Interferon gamma (IFNɣ), (Flaishon et al., 2000)
Vascular endothelial growth factor A (VEGF-a) (Kut et al., 2007) and Angiopoietin-2 (ANG2) (Nataraj et al., 1999; Bai et al.,
2014) hsCRP. (Seo et al., 2012) Before blood samples were taken, it was ascertained that the patient did not feel unwell, have
an infectious condition, or needed anti-inflammatory medication in the week before the samples were taken.
Inflammation-associated microRNAs: Targeted assessment of circulating (cell-free) inflammation-associated microRNAs miR-146a, miR-155, miR-21, miR-223,
and miR-132.(Tahamtan et al., 2018) miR-146a and miR-155 are linked to inflammation and miR-21, miR-132, (Hewitson
et al., 2019) miR-155 (Yee et al., 2017) are all linked to angiogenesis and vascular inflammatory responses
Chronic accumulative stress:
Hair cortisol levels
Cortisol hair test was used as biomarker for chronic accumulative stress.(Staufenbiel et al., 2013) Hair samples were chosen
as levels of the hormone in the blood and saliva can rapidly fluctuate, giving a poor picture of long-term concentrations.
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3.1.2. Recruitment
Recruitment and assessment was supported by the TEWV R&D
department for different sites, recruitment was planned until June 1st,
2020. Setting up sites was feasible. Access to medical history data to
decide on eligibility of patients was mostly provided by referring psy-
chiatrists and from GP practices, but not always straightforward as the
records were not always complete regarding letters of neurologists de-
tailing their diagnostic assessments. An amendment to the consent pro-
cess to allow access to pertinent information from participants’ GP
records was submitted in February 2020. Research nurses and study team
members were trained in the study procedures and administration and
the scoring of the questionnaires in the case report form (CRF). Many
participants were not able to travel so it was important to involve col-
leagues who were willing to visit participants in their own homes or their
local hospital/clinic. Disclosure and Barring Service (DBS) checks and
research passports had to be obtained. Four psychiatrists were trained
and supported by a format in the CRF for the procedures for the psy-
chiatric assessment. Following the introduction of the COVID-19 re-
strictions the assessments were carried out by video link. After ending the
recruitment phase, the CRF format was audited and found feasible to
complete. Its layout was improved based upon the audit. Three people
were trained and supervised by a clinical psychologist in the adminis-
tration of the neuro-cognitive tests. Testing and supervision went as
planned.
3.1.3. COVID-19
Owing to the COVID-19 outbreak recruitment was suspended from
March 2020 for the full further planned recruitment period, shortening it
by 4 months. Because of this, seven patients identified as eligible were
unable to consent and to be included in the study. Some face-to-face
assessments, clinimetric assessments and one blood sampling in pa-
tients already recruited could not take place. At the time of the first UK
COVID-19 lockdown (March 2020) the Humber NHS Teaching Founda-
tion Trust had begun recruiting and the research teamwere in the process
of setting up sites at York Teaching Hospital and a stroke unit in South
Tees, as well as exploring how searches of GP records might be con-
structed for identifying this patient group. Although we don’t have a full
data set on some variables, it is reasonable to suppose on the evidence
from this study and conversations with participants and sites that
collection of these data is feasible and acceptable.
3.1.4. Participants
Between August 2019 and March 2020, 95 potential participants had
been identified through clinics at TEWV and Humber Teaching NHS
Trusts before the study had to close prematurely. Of these, 13 met the
criteria for recruitment and gave consent to join the study. Five further
participants heard about the study and contacted the study team directly.
Of these five, one was ineligible and four consented of whom two were
prevented from meeting with the study team due to COVID-19 re-
strictions. As the flowchart in Fig. 1 shows, the closure of all non-COVID-
19 related research had a considerable impact on study recruitment as
Humber Teaching NHS Foundation Trust was starting recruitment and
the TEWV medically unexplained physical symptoms (MUPS) clinic,
closed from December 2019 until March 2020, was re-opening. From
March 2020, the team started with data entry, lab analysis and statistical
analysis, and the reporting phase of the study.
3.1.5. Sites
During the set-up period the study team was contacted by several
mental health NHS trusts through the Clinical Research Network (CRN)
portfolio, expressing an interest in taking part. We have also had interest
from, and spoken to, neurologists, stroke units, pain clinics and physio-
therapists, and more recently from individuals and charities. All of the six
GP practices we consulted in and around York were also keen to be
involved. Expanding the network of collaborators within the NHS and
establishing a larger cohort is unlikely to be too difficult given
appropriate time and resources. Collaboration and knowledge exchange
within and outside the interdisciplinary team of researchers has been key
to the conduct of and learning from this feasibility study. In view of this
the indications are that recruiting amuch larger cohort would be feasible.
3.2. PPI involvement and feasibility from the participant perspective
The number of patients identified through each of the recruitment
methods and the proportion of those who were willing and eligible to
take part were recorded. Willingness to complete assessment processes
was monitored including attrition rates and reasons, to identify any
barriers to completion. Themajority of participants were able and willing
to complete every part of the study. All participants recruited to the study
completed all the questionnaires. Five participants preferred to have
their responses written by the researcher because writing was difficult.
Three participants did not complete any of the neuro-cognitive tests and
the psychiatric assessments. One found the tests too difficult because of
speech problems, one was too busy and one who was recruited shortly
before the COVID-19 restrictions were put in place and the test had to be
cancelled. A further four participants completed the psychiatric assess-
ment by video link following the lockdown but have not been able to do
the face-to-face neuro-cognitive tests.
The processes associated with the study were assessed for accept-
ability to participants and HCPs, canvassing views of both. All partici-
pants in the study were invited to provide feedback on study procedures
and patient materials as part of the study. Additionally, we recruited
interested people with lived experience of the condition to advise on and
contribute to dissemination of the study findings and the design and
management of future research projects. Participants were consulted
individually and during study PPI group meetings. There was general
agreement that the study procedures and the questionnaires were
acceptable to participants despite some challenging content. The ques-
tionnaires took between 20 and 95 min to complete which was longer
than anticipated in some cases, but participants appeared to be enlivened
by taking part rather than tired by it. This was confirmed in subsequent
discussion with participants. They liked the patient information booklet
and found all the study documents easy to use.
3.3. Patient characteristics
Fifteen people participated in the study, 8 female. Demographic and
clinical characteristics are shown in Table 2.
Participants were aged between 23 and 63 (mean 49.7) years; mean
54 years in males, 46 years in females. All described themselves as white
British. Educational level was secondary school for 6, college or univer-
sity for 7 and postgraduate for 1 participant Five were employed, in
education or a homemaker, 8 were unable to work and 1 was retired.
Mean main symptom severity was 8.73 out of 10 and mean duration of
symptoms was 69 months; more than 5 years.
All participants had CD/FND according to DSM-5 criteria. The main
reported symptoms were difficulty walking (12, 80%); muscle weakness
or paralysis to some extent (12, 80%); and tremor or shaking (11, 73%).
Sensory symptoms such as numbness or tingling were reported in 11
(73.3%) cases. 9 (60%) have blurred vision, 1 patient (6.7%) was
sometimes blind. Eight (53%) suffered some kind of loss of voice, and 2
(13.3%) suffered from deafness. One participant had experienced sei-
zures in the past but not during the episode with CD/FND. Three par-
ticipants had only motor CD/FND; the rest of the cases were mixed CD/
FND.
Mean MMSE scores (n ¼ 8) were 28.9 (SD1.4) range 27–30. CGI
scores (n ¼ 9) were mean 4.7 (SD 1.3) with a range between 3 and 7.
3.4. Physical symptoms and quality of life
Mean PSQ-51 score was 60 (SD ¼ 20) out of 88. Regarding the
symptom domains, the mean CD/FND symptom load was 8.5 (SD ¼ 3.5)
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out of 15. The mean digestive symptom load was 14.8 (5.6) out of 26;
mean pain score was 13.1 (SD 6.7) out of 24 and only one patient re-
ported no pain. Average fatigue scores were 4.5 (1.7) out of 6. All patients
reported sleeping problems with mean 3.2 (SD ¼ 1.9) out of 6. The
average for sexual problems was 1.7 (SD ¼ 1.6) out of 4. Pain assessed
with the BPI showed that 11 of the 15 patients (73%) had an average
score of 3 or more on the BPI in the last week and the whole sample had
as mean score 5.2 (SD 2.7).
Only one participant had no comorbid medical conditions. The range
was 0–16 chronic medical conditions and the average was 6.1. They had
an average of 2.9 comorbid somatic comorbid medical conditions such as
diabetes, cardiovascular disorder or COPD; and 3.3 comorbid functional
Fig. 1. Flowchart CANDO study.
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disorders like burnout, depression, anxiety disorders or digestive tract
problems like Irritable Bowel Syndrome, or unexplained pain.
On the EQ-5D-5L, 67% reportedmoderate to severe mobility problems.
53% reportedmoderate to severe self-care problems, 60%hadmoderate to
severe problems with usual activities, 60% had moderate to severe pain/
discomfort and 60% had moderate to severe anxiety or depression. The
mean score for the general health item was 45.5 (SD ¼ 21.4).
RAND SF-36 scores are shown in Table 3. Norm scores of the MOS are
shown for comparison and p-values presented for the differences by one
sample t-test.
All sample scores are significantly lower and the mean differences are
large, indicating that the participants in this sample had much worse
functioning in all domains than clinical patients with chronic medical
conditions in the MOS study.
3.5. Comorbid depression and anxiety
All patients scored above the level of mild depressive symptoms
(PHQ-9 scores above 5). Only 2 were below 10 indicating a probability
for a depressive disorder (mean14.4, SD ¼ 4.6).
On the GAD-7, two participants (13%) did not report anxiety levels.
Three (20%) scored mild anxiety and 10 (67%) score 10 or higher,
indicating a probable anxiety disorder (mean ¼ 10.9, SD ¼ 4.8).
3.6. Trauma and stress
Findings are shown in Table 2. Regarding childhood trauma, two
participants (13%) experienced no Adverse Childhood Experience (ACE).
One participant (7%) experienced 1 ACE. 80% experiencedmultiple ACE,
60% experienced 3 or more ACE and themaximum number of ACEwas 7.
The average ACE score was 4.0 (SD ¼ 2.4). The scores on the 10 ACE
domains indicated that during childhood, one person was married
without her consent; three (20%) were a victim of childhood sexual
abuse; eight patients (53%) reported parental neglect; eight (53%) re-
ported external violence such as being beaten up, 9 (60%) were a victim
of domestic abuse; 10 (67%) reported parental illness; 10 (67%) wit-
nessed domestic abuse; and 11 (73%) experienced bullying. Nobody re-
ported war experiences during childhood.
Regarding current stressful life events, the average LCU score in the
sample was 234 (SD¼ 134). 27% of the participants scored less than 150,
40% scored between 150 and 299 and 33% scored 300 or higher. These
scores indicate very high stress levels requiring role adaptations in daily
life to a great extent.
3.7. Neurocognitive functioning
TOMM Trial 1 test mean score was 47.0 (SD 2.4), median ¼ 46 (SD
2.4), range¼ 6 (44–50). TOMM Trial 2 test mean score was 50.0 (SD 0.0)




Age Mean: 49.7 years
Range: 23–63 years
Gender Female (n ¼ 8; 53.3%)
Male (n ¼ 7; 46.7%)
Ethnicity White British (n ¼ 15; 100%)
Education level Secondary/High School (n ¼ 6; 40%)
College/University (n ¼ 7; 46.7%)
Postgraduate Degree (n ¼ 1; 6.7%)
Missing (n ¼ 1; 6.7%)
Work status Employed (n ¼ 3; 20%)
Student (n ¼ 1; 6.7%)
Homemaker (n ¼ 1; 6.7%)
Retired (n ¼ 1; 6.7%)
Unemployed/unable to work (n ¼ 8; 53.3%)
Missing (n ¼ 1; 6.7%)
Relationship status Single (n ¼ 2; 13.3%)
In a relationship (n ¼ 1; 6.7%)
Married (n ¼ 7; 46.7%)
Divorced/Separated (n ¼ 3; 20%)
Widowed (n ¼ 1; 6.7%)
Missing (n ¼ 1; 6.7%)
Height (cm) N ¼ 8; mean¼ 167.7 cm (SD¼ 9.6; range 153–185)
Weight (kg) N ¼ 7; mean ¼ 85.7 kg (SD ¼ 21.1; range 57–125)
BMI N ¼ 7; mean ¼ 30.15 (SD ¼ 7.0; range 20–41).
Waist circumference (cm) N ¼ 5; mean 88.73 (SD ¼ 13.99; range 71–107)
Systolic blood pressure (mm
Hg)
N ¼ 5; mean 149.0 (SD 29.1), range 120–188.
Diastolic blood pressure (mm
Hg)
N ¼ 5; mean 81.2 (SD 6.6), range 74–92
Severity of main symptom Mean ¼ 8.73 (SD ¼ 1.831)
Mean duration of symptoms 69.4 months
Main reported symptoms Difficulty walking (n ¼ 12; 80%)
Muscle weakness or paralysis to some extent (n ¼
12; 80%)
Tremor or shaking (n ¼ 11; 73%)
Sensory symptoms (numbness or tingling) (n ¼ 11;
73.3%)
Blurred vision (n ¼ 9; 60%)
Temporary blindness (n ¼ 1; 6.7%)
Loss of voice (n ¼ 8; 53%)
Deafness (n ¼ 2; 13.3%)
CD/FND Type Mixed CD/FND (n ¼ 12; 80%)




n ¼ 8; mean ¼ 28.9 (SD ¼ 1.4; range 27–30)
Clinical Global Impression
(CGI) score
n ¼ 9; mean ¼ 4.7 (SD ¼ 1.3; range 3–7)
Adverse Childhood
Experience (ACE) score
N ¼ 15; mean ¼ 4 (SD ¼ 2.4; range 0–7).
ACE domains:
Married without their consent ¼ n ¼ 1
Victim of childhood sexual abuse ¼ n ¼ 8
Parental neglect ¼ n ¼ 8
External violence ¼ n ¼ 9
Victim of domestic abuse ¼ n ¼ 9
Parental illness ¼ n ¼ 10
Witnessed domestic abuse ¼ n ¼ 10
Victim of bullying ¼ n ¼ 11
War experiences during childhood ¼ n ¼ 0.
Life Change Unit (LCU) score N ¼ 15; mean ¼ 234 (SD ¼ 134; range 0–483).
(4 participants scored <150, 6 participants scored
between 150 and 299, 5 scored >300).
Table 3
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any study participant. Table 4 presents the neurocognitive tests with raw
scores and corresponding norm-referenced scaled scores. All scaled
scores have a normative standardised population mean of 10 (SD 3.0).
Scores below 7 would indicate a difference of >1 SD from the population
mean and are interpreted as impaired for the purpose of this study.
Average scores on the Colour Word Interference Test (a timed test of
cognitive flexibility, inhibition and switching) indicated impairment
across conditions. Impaired scores on Conditions 1 and 2, relative to the
population norm, suggests slowed information processing overall.
Impaired mean scores on Conditions 3 and 4 indicates that participants
had difficulties with inhibition and switching in relation to visual
attention but it is possible that this was subject to slowed information
processing overall given evident impairment on Conditions 1 and 2.
TMT visual scanning mean scores appeared impaired whereas num-
ber sequencing and letter sequencing were normal. The number letter
switching condition is a key test of executive functioning, and mean
scores here appeared impaired. However, this might be subject to
impaired motor speed (Condition 5).
Scores on the WAIS digit symbol substitution test mean scores
appeared to be in the normal range overall but some individuals showed
impairment.
Total scores on the WAIS Digit Span Score appeared normal and there
were no anomalous disparities between digits forwards and backwards
conditions, indicating effort was not impaired overall.
Scores on the Tower of London Test (a measure of executive func-
tioning in terms of visual memory and problem solving and rule
following) were in the normal range; some participants performed
particularly well on this test (scaled scores ranged from 9 to 16).
3.8. Biomarkers
3.8.1. Clinimetric measures
These measures and the number of patients that could be assessed are
shown in Table 2.
3.8.2. Cytokines and hsCRP
Table 5 shows the cytokine scores compared with the normal sample
for the study sample (N ¼ 14) compared with cut-off score.
Based upon this, for IL1B, 13 (93%) was normal, 1 (7%) was elevated.
The median score of IL1B in this sample did not differ significantly from
the median in the normal sample (p ¼ .317).
Scores were elevated (100%) compared to the median from the
normal sample and a Wilcoxon Signed Rank Test showed that this was
significant (p ¼ .001) for IL-6, IFNγ, IL17A, IL12 and TNFα. The VEGF-a
score was significantly lower compared to the median of 54.5 in the
normal sample (p ¼ .005).
Angiopoietin-2 (ANG2) is involved with inflammation-induced
vascular remodelling. Healthy plasma concentrations for ANG2 range
between 1800  874 pg/ml) (Li, 2015), or between 1-3μg/ml(Thurston,
2012). From that perspective, the ANG2 levels in our sample score in the
normal range. To summarise, our sample shows significantly elevated
IL-6, IFNγ and TNFα and significantly lower VEGF-a.
For hsCRP, 11 (79%) were normal, 3 (21%) were elevated (Ridker
et al., 1998). A one-sample t-test showed that the mean hsCRP score was
significantly lower than the cut-off score of 3.0 mg/ml; mean difference
1.35 (95% CI: 2.53;-0.18); p¼ .027). However, it was not undetectable.
Although hsCRP can be detected in systemic low grade inflammation
patients, in this sample it does not seem to be a useful biomarker.
3.8.3. microRNA
There is extensive literature linking several miRNAs to inflammation
and neuroinflammation as well as pain (Andersen et al., 2014; Mi et al.,
2013). We supplemented our analysis of circulating cytokines in the
cohort by measuring levels of 5 miRNAs associated with inflammation
(miR-146a, miR-223 (Wang et al., 2010) miR-155 (Alivernini et al.,
2018; Singh et al., 2019)) and to angiogenesis and vascular inflammatory
responses (miR-21 (Liu et al., 2011; Sheedy et al., 2010; Du et al., 2019),
miR-132 (Kumarswamy et al., 2014) and miR-155 (Singh et al., 2019))
and miR-16, a highly abundant miRNA in circulation.
We observed a range of miRNA blood plasm levels within the cohort
as shown in Fig. 2.
We also explored if levels of miRNAs correlated with levels of TNF in
the cohort. We found that this was the case for all tested miRNAs. How-
ever, more significant Pearson P correlations (p< .005) were observed for
each miRNA against TNF (analysed with GraphPad Prism). Fig. 3
We specifically explored the correlation of VEGF with miR-132 and
miR-21 as both of these miRNAs have been extensively linked to angio-
genesis and endothelial cell function (Anand et al., 2010; Lagos et al.,
2010; Kumarswamy et al., 2014; Liu et al., 2011; Luo et al., 2017; Du
et al., 2019), as shown in Fig. 4.
These correlation plots show a split of our patient group into two
distinct groups: one with good correlation betweenmicroRNAs and VEGF
and one with very low microRNA levels and no correlation.
Table 4
Outcome of neurocognitive testing (N ¼ 8).










5,50 (SD 4,28) Impaired
Condition 2 Word reading 34,03 (SD
11,12)
5,25 (SD 4,23) Impaired
Condition 3 Inhibition 84,08 (SD
28,67)





5,00 (SD 3,85) Impaired
Trail Making Test (TMT)
TMT Visual scanning 40,46 (SD
16,52)
5,00 (SD 4,57) Impaired
TMT Number sequencing 55,4063 (SD
25,97)
7,50 (SD 4,41) Normal
TMT Letter sequencing 59,06 (SD
25,68)





6,13 (SD 3,80) Impaired
TMT Motor speed 77,70 (SD
58,80)
6,63 (SD 4,69) Impaired
WAIS Digit Symbol Substitution Test
Coding score 53,38 (SD
16,03)
8,63 SD (2,50) Normal
WAIS Digit Span Test
Total score 28,13 (SD 4,52) 11,13 (SD
1,89)
Normal
Tower of London Test














13.2 3.8 [0.46–22.8] p ¼ .001
IL-6 .964 (.571) .85 0.29 [0.12–0.99] p ¼ .001
TNFα 2.486 (.783) 2.50 0.74 [0.31–2.32] p ¼ .001
IL-1b .214 (0.535) .200 0.2 [0.11–0.94] p ¼ .317
VEGF-A 29.58
(18.84)






3.350 0.59 [0.22–8.51] p ¼ .001
IL12 220.221
(164.085)
183.5 62.5 [15.1–395] p ¼ .001
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3.8.4. Cortisol
Hair cortisol findings in both samples are shown in Table 6.
Hair samples were taken in 14 participants, however hair samples
need to weigh at least 25 g to assess, and in nine patients this was
impossible to obtain because of hairstyle; hence only 5 samples were
eligible to be assessed. They were compared with 5 healthy samples
obtained and assessed in the same manner. The CANDO healthy sample
was taken at the beginning of the lockdown. The last month levels in the
healthy sample indicate levels at the beginning of lockdown (March
2020). The earlier healthy samples indicate levels approximately 1
month before the COVID-19 outbreak and lockdown. None of the levels
differed significantly within the samples and there was no significant
difference between the samples. The means were in the normal score
ranges (Herane-Vives et al., 2018).
4. Discussion
4.1. Feasibility
We found that 85% of people approached could be recruited. Because
of COVID-19, recruitment had to be stopped in 7 potential participants
(27%). A variety of sites were interested in participating including sites
outside mental health NHS trusts, such as neurology departments,
physiotherapy practices, and primary care sites. Data were complete with
an attrition rate of 13% before COVID-19 halted the study. We were also
able to develop a reliable network for the collection, appropriate storage
and transport to laboratories of samples ensuring valid test outcomes.
Study procedures were acceptable for participants, in terms of tolerance
for the duration of interviews, blood sampling and potentially distressing
revisiting of past events, as well as willingness to attend psychiatric
assessment. Participants were positively engaged and other members of
the public engaged spontaneously. There was a general consensus that
this condition is understudied and the PPI group supported this initiative
wholeheartedly, which underscores the high clinical unmet need, the
acceptability of the study procedures to patients and carers, and the wish
of patients and carers to support research in this domain. As with most
research studies, getting the design right, study set-up, obtaining ap-
provals and recruiting to time and target are major challenges. This
feasibility study has given the study team and collaborators the oppor-
tunity to refine the design and establish the networks needed for a full-
scale trial. We now know a lot more about how and where to recruit
participants other than through mental health NHS organisations. Also
we know that patients may self-refer. A greater challenge than antici-
pated was the determination of potential eligibility from secondary care
medical records. A two-part consent procedure might also be considered
for a larger cohort. There is a need to include a mechanism for obtaining
GP data which we would have if we were recruiting through primary
care. We would then also possibly get a more representative sample. As
each of the criteria that we set when we designed the study (Van der
Feltz-Cornelis et al., 2020b) have been met, the evidence suggests that
setting up a larger cohort would be feasible and valuable.
4.2. Characteristics of the patient group
Not only have the assessments proven to be mostly feasible, the
outcomes also give an indication that this is a highly vulnerable patient
group. Both physical and psychological symptom levels are high, co-
morbidity with other mental disorders such as depression and anxiety is
high and physical symptoms not only occur in the domain of CD/FND,
but also in other physical domains, even though we took great care to
exclude patients with clear-cut inflammatory diseases or brain pathology.
Quality of life was much worse than at population level in a developing
country such as Indonesia (Purba et al., 2018). Levels of functioning in all
domains of the RAND SF-36 were much worse than in clinical patients
with chronic medical conditions in an USA sample (Tarlov et al., 1989). A
similar finding has been reported in Somatic Symptom Disorders and
Related Disorders, of which CD/FND is a subsection, where patients with
SSRD without known chronic medical condition reported worse func-
tioning levels than patients with SSRD with known chronic medical
condition(Van der Feltz-Cornelis et al., 2020a). An explanation of this
finding might be that levels of distress interfere with quality of life and
general functioning and are worse in case of unexplained, very disabling
physical symptoms, compared to disabling physical symptoms due to a
known chronic medical condition. Actual stress levels as measured by the
LCU are strikingly elevated with only 27% of the patients scoring less
than 150, which is associated with higher levels of depression (Cornelis
et al., 1989), or being in a crisis (Holmes and Rahe, 1967). 30% scored
300 or higher, which is associated with elevated risk for an accident or
physical disease (Rahe et al., 1970; Rahe and Arthur, 1978). Such high
symptom load and low functioning has also been described in patients
with a different kind of CD/FND, namely patients with psychogenic
non-epileptic seizures. They showed high comorbidity, and also higher
mortality than the general population of a similar level as patients with
epileptic seizures (Nightscales, 2020), indicating that CD/FND may not
be a harmless condition to suffer from.
4.3. Adverse childhood Experience(ACE)
Regarding childhood trauma, 86% experienced at least one ACE
which is substantially more than the 64% in the original N¼ 17,000 ACE
Fig. 2. Plasma miRNA levels within the CANDO cohort (N ¼ 14). For each miRNA, levels were normalised to spike-in control and average levels within the cohort
(LEFT panel), or spike-in control, miR-16, and cohort average levels (RIGHT panel).
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study conducted in the USA general population (Centre of Disease Con-
trol and Prevention, 2016). It is also more than the 77% reported in
mental health outpatients with anxiety or depression (Van der
Feltz-Cornelis et al., 2019b), and more than 61.8% reported in out-
patients with SSRD (Van der Feltz-Cornelis et al., 2020a). 80% experi-
enced multiple ACE and the mean ACE score was 4 which is high
compared to these studies as well. Childhood sexual abuse occurred in
this sample and this is clinically relevant as this has been found to
negatively influence treatment outcome in CD/FND. (Van der
Feltz-Cornelis et al., 2019a) A recent study found that childhood physical
neglect is associated with exaggerated systemic responses to short-term
exposure to psychosocial distress in the Trier Social Stress Test, in
which reactive gene expression might play a role (Schreier et al., 2020).
As mean IL-6 scores in that study are much lower than in our sample,
elevated cytokines in CD/FND may have other drivers than ACE as well.
Fig. 3. Correlations between levels of tested miRNAs (normalised to spike-in control) against levels of TNF for each participant (N¼13).
Fig. 4. Correlations between levels of tested miR-132 and miR-21 (normalised to spike-in control) against levels of VEGF-a for each participant (N ¼ 14).
Table 6
Hair cortisol levels in both samples.
Sample CANDO N ¼ 5 p-
value



























Median 9.94 9.86 7.64 6.53
Range 11.85 14.65 21.54 14.94
Min 3.90 6.48 6.42 3.74
Max 15.75 21.13 27.96 18.68
p-value comparing CANDO sample with healthy sample .864
C. van der Feltz-Cornelis et al. Brain, Behavior, & Immunity - Health 13 (2021) 100228
9
The hair cortisol levels in our sample were in the normal range,(Meyer
and Novak, 2012) suggesting that HPA axis pathology did not play a role
in this. In future studies, exploring the link between ACE, current stress,
cytokines and microRNA in CD/FND should therefor certainly be
pursued.
4.4. SLI, microRNA and epigenetics
Our study sample showed elevated IL-6, IFNγ, IL17A, IL12 and TNFα
scores, normal IL1B scores, and VEGF-a scores significantly lower
compared to the normal sample. Another study in acute CD/FND patients
found elevated IL-6, TNFα and IL1B scores (Tiyekli, 2013), which is
different from our findings as in our study, IL1B was normal. Dysregu-
lated continual synthesis of IL-6 plays a role in pathologic chronic
inflammation and autoimmunity (Tanaka, 2014) so our study supports
the idea that IL-6 may play a role in CD/FND of longer duration. IFNγ is
produced by CD4þ T helper 1 cells (Th1 cells). It plays a key role in B cell
maturation, as it works to inhibit migration into lymph nodes while the B
cells are still immature (Flaishon, 2000) and inhibits proliferation of T
cells (Chu, 2000). Tumour Necrosis Factor Alpha (TNFα) is produced by
macrophages/monocytes during inflammation and has widespread
cellular effects, although still a great deal is unknown about its function
and complex interplay with other cytokines (Zelova, 2013). IL-12 plays
an important role in the activities of natural killer cells and T lympho-
cytes and has anti-angiogenic activity, which means it can block the
formation of new blood vessels by increasing production of IFNγ and
chemokines. Also, regarding vascular endothelial growth factor A or
VEGF-a, we found significantly lower scores than in a healthy sample.
VEGF-a was named after its role in angiogenesis. The VEGF-a serum level
is elevated in coronary artery disease (CAD) and low serum VEGF-a has
been found to indicate severe coronary artery lesions and a higher
GRACE score, indicating poor clinical outcomes (Huang et al., 2020). Too
low VEGF can lead to decreased angiogenesis and lack of oxygen to the
tissues. It would be worthwhile to explore if this might also pertain to
brain ischemia and neurodegeneration. There is emerging evidence that
VEGF-a has effects on neural development, and VEGF-a changes could be
linked to neural changes in adulthood, for astroglia and Schwann cells,
supportive cells to neurones providing metabolic support and recycling
neurotransmitters released into synapses (Mackenzie, 2012). It could be
assumed that changes in VEGF-a could result in disruption in neurone
nourishment, health and regulation. To summarise, our findings show an
elevation of cytokines across the board, indicating peripheral inflam-
mation; links to T cell activity; and to reduced angiogenesis and support
to neuronal cells.
Our study suggests epigenetic processes as TNFα was correlated with
miR-16, miR-132, miR-146a, miR-155, miR-223 and miR-21. miR-146a
is known to be associated with inflammation and so is miR-155 (Yee,
2017). Also, regarding the association between microRNA and VEGF-a,
we found two subgroups in our sample. One with a correlation be-
tween miRNA-21 and miRNA-132, both microRNAs implicated in
vascular inflammation, and VEGF-a levels, and one with very low
microRNA levels and no correlation. This suggests that there may be an
epigenetic mechanism for a subgroup of patients with motor CD/FND. It
might be indicative of an important role for the vascular and circulatory
system in a subset of individuals with FND/CD. Suggestions for some
vascular link have beenmade in a case study (Gürses et al., 2008) and in a
recent review considering that a proportion of patients entering the care
pathway present with functional symptoms mimicking stroke or have
functional symptoms in addition to vascular stroke (Jones et al., 2020).
The possibility that VEGFa and microRNAmight play a role in this should
be investigated in future studies.
4.5. Neurocognitive impairments
Neurocognitive tests showed no indications of impaired effort ac-
cording to the WAIS Digit Span Scores and no evidence of malingering in
the TOMM test. There was evidence of impairment in verbal and visual
components of executive functioning (inhibition/switching on the CWIT
and TMT). Equally, there was evidence of slowed information processing
and motor speed overall, which could influence higher executive func-
tions involving cognitive flexibility under timed conditions, such as in-
hibition and switching. Conversely, executive functions assessed by the
WAIS digit symbol substitution test and the Tower of London Test (also a
timed task) were in the normal range. If we compare these findings with
findings with a sample of 29 patients with CD/FND, raw scores on both
the (Stroop) CWIT test and TMT (visual scanning) were substantially
lower in the current sample (De Vroege et al., 2020). Working memory
scores were slightly higher in the current sample although still impaired.
This warrants further, larger scale research in order to more fully
establish a profile of neurocognitive impairment in this group and its
association with neuro-inflammation markers as well as self-reported
stress and adverse childhood experiences.
4.6. Implications for research
This feasibility study shows that there is scope to further explore an
underlying pathogenic mechanism related to an inflammatory process
and vascular inflammatory process in CD/FND with motor problems,
cytokines, and the role of miRNA. Our results provide support for further
studies investigating the role of inflammation in CD/FND pathogenesis.
Understanding the links between inflammation and CD/FND pathogen-
esis can potentially lead to inclusion of anti-inflammatory agents in
future research evaluation of new treatments for CD/FND. VEGF-a might
be explored further. The role of microRNA needs further exploration, as
mental disorders have been suggested to result from impairments in
cellular plasticity cascades, disrupting cellular networks, rather than
disturbances in any particular monoamine system. Such impairments
may lead to aberrant information processing in the brain circuits that
regulate mood, cognition, and neurovegetative functions. MicroRNAs are
non-coding RNAs that can repress the gene translation of hundreds of
their targets and are therefore well-positioned to target and impair a
multitude of cellular mechanisms. They are altered by stress, glucocor-
ticoids, and mood stabilizers (Hunsberger, 2009). The contribution of
brain miRNAs to the regulation of behaviour may play a key role in the
epigenetic hypothesis for mental disorders (Issler, 2015). miRNA levels
may potentially be used in the diagnosis of mental disorders and might
become novel treatment targets for mental disorders (Hanna et al.,
2019). Another avenue for future research may be developing and
evaluating a cognitive remediation training aimed at maintaining,
switching and focusing attention, such as in brain injury patients. It is
already common practice to work on attention before starting CBT in
dementia patients in order to compensate for age-related changes in
executive functioning and attentional skills, and this might be a path to
explore in CD/FND patients as well, taking different cytokine and miRNA
profiles into account towards the intervention.
4.7. Limitations of the study
This is a feasibility study that has obvious limitations. Firstly,
although the study was getting set up to include patients from several
NHS settings, due to the COVID-19 outbreak, most patients were
recruited from a single NHS trust, limiting our knowledge of how the
processes may work in other settings. Nevertheless, as other settings were
starting up to contribute, we have no reason to doubt the feasibility of
having multiple sites and settings contribute. Second, patient charac-
teristics provide an indication of the potential relevance of further
research to explore the hypothesis that systemic low-grade inflammation
and microRNA might play a role in CD/FND; further research would be
needed to explore this. Third, regarding the cytokines and microRNA, we
only had one sample, taken at a random sample timepoint and not related
to an intervention. Although we made an effort to not include patients
with evidence of a concurring inflammatory condition, two baseline
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measures to check if an elevated score would not be temporary and
related to a passing infection, but an indication of systemic low-grade
inflammation, would have been a good addition. Fourth, although we
found some statistically significant findings, and we compared with re-
sults from a healthy sample following the same methods at the same lab,
the generalisability of the results is limited because of the small number
and the lack of a control group that was matched for age and gender and
examined at the same time as the patients. Also, in a future study we will
need procedures to assess BMI and weight circumference in patients
unable to stand, as well as smoking, (Yudkin et al., 1999) to enable us to
correct for confounding factors.
4.8. Strengths of the study
This study has several strengths. We evaluated the feasibility to assess
stress-related SLI in CD/FND patients with prevalent motor function
FND, which is a very vulnerable population. The key strengths of this
study are the use of both objective and subjective observational methods
to assess stress related SLI, psychological and cognitive symptoms in this
sample population. This is the first study exploring not only clinical
characteristics regarding the condition itself, but also cytokines, micro-
RNA, hair cortisol, and several variables exploring psychiatric comor-
bidity, current stress and trauma, and neurocognitive functioning. The
finding that it is feasible to do such a comprehensive assessment in so
vulnerable patients in a limited amount of time is important for the
development of work in CD/FND. Furthermore, the findings suggest that
there are indications for SLI in this condition as participants demon-
strated elevated levels of inflammatory cytokines which correlated with
levels of inflammation-associated and vascular inflammation associated
miRNAs within the cohort. It is a strength of the study that the selection
of a homogeneous group and the combination of cytokines and micro-
RNA enabled us to find two subgroups regarding VEGF-a, indicating
possible different mechanisms that may be helpful in future profiling
studies (Van der Feltz-Cornelis, 2020c). Also, the finding that the par-
ticipants evaluated the study positively and that patients were eager to
engage is a strength of the study. These findings support the further
development of a larger project aiming to explore this further and to
develop new treatments for this population in the future.
5. Conclusion
This innovative, translational study explores stress-related SLI in CD/
FND patients and the feasibility of a larger project aiming to develop new
treatments for this vulnerable population. It provides knowledge about
levels of SLI, psychological and neurocognitive symptoms in patients
with CD/FND that is so far largely unknown and warrants further
research. Furthermore it provides valuable knowledge regarding the
feasibility of conducting a study in these patients that will inform future
study phases. Given the positive findings, there is scope to conduct
further research.
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